Last reviewed · How we verify
rurioctocog alfa pegol
At a glance
| Generic name | rurioctocog alfa pegol |
|---|---|
| Also known as | recombinant intravenous factor VIII, Adynovi® |
| Sponsor | Spanish Society of Thrombosis and Haemostasis |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
- Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A (PHASE1)
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A (PHASE3)
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
- Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
- Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rurioctocog alfa pegol CI brief — competitive landscape report
- rurioctocog alfa pegol updates RSS · CI watch RSS
- Spanish Society of Thrombosis and Haemostasis portfolio CI